AU2016270504A1 - Liquid formulations of celecoxib for oral administration - Google Patents

Liquid formulations of celecoxib for oral administration Download PDF

Info

Publication number
AU2016270504A1
AU2016270504A1 AU2016270504A AU2016270504A AU2016270504A1 AU 2016270504 A1 AU2016270504 A1 AU 2016270504A1 AU 2016270504 A AU2016270504 A AU 2016270504A AU 2016270504 A AU2016270504 A AU 2016270504A AU 2016270504 A1 AU2016270504 A1 AU 2016270504A1
Authority
AU
Australia
Prior art keywords
celecoxib
pharmaceutical preparation
preparation according
liquid pharmaceutical
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016270504A
Other languages
English (en)
Inventor
Thomas Jeffrey Bryant
Jeffrey Scott Kiel
Richard Gerard Levasseur
Hugh Greg Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CODADOSE Inc
Original Assignee
CODADOSE Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CODADOSE Inc filed Critical CODADOSE Inc
Publication of AU2016270504A1 publication Critical patent/AU2016270504A1/en
Assigned to CODADOSE INCORPORATED reassignment CODADOSE INCORPORATED Request for Assignment Assignors: KIEL LABORATORIES, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
AU2016270504A 2015-05-29 2016-05-24 Liquid formulations of celecoxib for oral administration Abandoned AU2016270504A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562168012P 2015-05-29 2015-05-29
US62/168,012 2015-05-29
US15/163,258 US20160346300A1 (en) 2015-05-29 2016-05-24 Liquid formulations of celecoxib for oral administration
PCT/US2016/033937 WO2016196085A1 (en) 2015-05-29 2016-05-24 Liquid formulations of celecoxib for oral administration
US15/163,258 2016-05-24

Publications (1)

Publication Number Publication Date
AU2016270504A1 true AU2016270504A1 (en) 2017-12-14

Family

ID=57396976

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016270504A Abandoned AU2016270504A1 (en) 2015-05-29 2016-05-24 Liquid formulations of celecoxib for oral administration

Country Status (9)

Country Link
US (1) US20160346300A1 (enExample)
EP (1) EP3302430A4 (enExample)
JP (1) JP2018516279A (enExample)
AU (1) AU2016270504A1 (enExample)
BR (1) BR112017025527A2 (enExample)
CA (1) CA2987388A1 (enExample)
MX (1) MX2017015202A (enExample)
RU (1) RU2017145602A (enExample)
WO (1) WO2016196085A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191744A1 (en) * 2015-05-28 2016-12-01 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
WO2022185338A1 (en) * 2021-03-05 2022-09-09 Alkem Laboratories Limited Stable oral suspension of celecoxib and method of preparation thereof
CN115737554B (zh) * 2022-11-28 2024-07-09 宜昌人福药业有限责任公司 一种氯巴占口服混悬剂的制备方法
WO2024142089A1 (en) * 2022-12-27 2024-07-04 Cipla Limited Injectable compositions of celecoxib

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145440A (en) * 1977-08-18 1979-03-20 The Upjohn Company Liquid suspension of an aluminum salt of ibuprofen
IN191512B (enExample) * 2000-01-21 2003-12-06 Panacea Biotech
MXPA02010259A (es) * 2000-04-18 2003-12-11 Pharmacia Corp Formulacion de accion rapida de un inhibidor selectivo de ciclooxigenasa-2.
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
PL371133A1 (en) * 2001-12-20 2005-06-13 Pharmacia Corporation Pharmaceutical suspension for oral administration
AU2003238221A1 (en) * 2002-06-17 2003-12-31 Taro Pharmaceuticals U.S.A, Inc. Ibuprofen suspension
US20060148877A1 (en) * 2002-11-26 2006-07-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050266031A1 (en) * 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US20110183944A1 (en) * 2010-01-28 2011-07-28 Paul Ashton SUSTAINED-RELEASE NSAID/HMG CoA REDUCTASE INHIBITOR COMPOSITIONS
EP3530268B1 (en) * 2012-10-09 2021-12-15 Attentive Therapeutics, Inc. Therapeutic treatment
CN103932977A (zh) * 2014-04-15 2014-07-23 江苏正大清江制药有限公司 一种塞来昔布制剂的制备方法

Also Published As

Publication number Publication date
MX2017015202A (es) 2018-07-06
RU2017145602A3 (enExample) 2019-11-25
CA2987388A1 (en) 2016-12-08
US20160346300A1 (en) 2016-12-01
WO2016196085A1 (en) 2016-12-08
RU2017145602A (ru) 2019-07-02
JP2018516279A (ja) 2018-06-21
EP3302430A4 (en) 2019-05-29
EP3302430A1 (en) 2018-04-11
BR112017025527A2 (pt) 2018-08-07

Similar Documents

Publication Publication Date Title
US10238640B2 (en) Pharmaceutical suspension composition
US8772317B2 (en) Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof
US20020037877A1 (en) Pharmaceutical suspension compositions lacking a polymeric suspending agent
KR101053780B1 (ko) 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
US8765150B2 (en) Riluzole aqueous suspensions
AU2016270504A1 (en) Liquid formulations of celecoxib for oral administration
WO2011156481A2 (en) Formulations including amiodarone and salts thereof and methods of their manufacture and use
CN1829503B (zh) 含有氟苯尼考的兽用水性可注射悬浮液
WO2023222660A1 (en) Aqueous ticagrelor solutions, method of manufacturing and uses
CZ20031612A3 (cs) Farmaceutický prostředek pro parenterální podání
WO2023222184A1 (en) Aqueous ticagrelor solution, method of manufacturing and uses
JP5391063B2 (ja) 安定な水性懸濁製剤
JP2023505255A (ja) 眼科用医薬組成物
EP1946747A1 (en) Pharmaceutical composition of improved stability containing taxane derivatives
JPH0536412B2 (enExample)
US20070244085A1 (en) Injectable or orally deliverable formulations of azetidine derivatives
JP4475405B2 (ja) 医薬組成物
WO2021033145A1 (en) Novel injectable formulations of artesunate
WO2023148763A1 (en) Injectable pharmaceutical compositions of azole antifungal agents
US20240415778A1 (en) Oral preparation containing progestogen, and preparation method and use
KR100299942B1 (ko) 비페닐디메칠디카르복실레이트의액제
WO2025172499A1 (en) Quetiapine liquid formulations
AU2015261543B2 (en) Controlled release compositions and their methods of use
US20230310417A1 (en) Injectable aripiprazole formulation
NZ608649B2 (en) Ionophore antibiotic suspension

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CODADOSE INCORPORATED

Free format text: FORMER APPLICANT(S): KIEL LABORATORIES, INC.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application